Cyclerion Therapeutics,Inc. (CYCN)
NASDAQ:CYCN
US Market
Holding CYCN?
Track your performance easily

Cyclerion Therapeutics (CYCN) Stock Price & Analysis

155 Followers

CYCN Stock Chart & Stats


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

CYCN FAQ

What was Cyclerion Therapeutics,Inc.’s price range in the past 12 months?
Cyclerion Therapeutics,Inc. lowest stock price was $1.75 and its highest was $5.25 in the past 12 months.
    What is Cyclerion Therapeutics,Inc.’s market cap?
    Currently, no data Available
    When is Cyclerion Therapeutics,Inc.’s upcoming earnings report date?
    Cyclerion Therapeutics,Inc.’s upcoming earnings report date is May 01, 2024 which is 140 days ago.
      How were Cyclerion Therapeutics,Inc.’s earnings last quarter?
      Cyclerion Therapeutics,Inc. released its earnings results on Feb 22, 2024. The company reported -$0.685 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.685.
        Is Cyclerion Therapeutics,Inc. overvalued?
        According to Wall Street analysts Cyclerion Therapeutics,Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Cyclerion Therapeutics,Inc. pay dividends?
          Cyclerion Therapeutics,Inc. does not currently pay dividends.
          What is Cyclerion Therapeutics,Inc.’s EPS estimate?
          Cyclerion Therapeutics,Inc.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Cyclerion Therapeutics,Inc. have?
          Cyclerion Therapeutics,Inc. has 2,710,096 shares outstanding.
            What happened to Cyclerion Therapeutics,Inc.’s price movement after its last earnings report?
            Cyclerion Therapeutics,Inc. reported an EPS of -$0.685 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.42%.
              Which hedge fund is a major shareholder of Cyclerion Therapeutics,Inc.?
              Among the largest hedge funds holding Cyclerion Therapeutics,Inc.’s share is Slate Path Capital LP. It holds Cyclerion Therapeutics,Inc.’s shares valued at 823K.
                ---

                Cyclerion Therapeutics Stock Smart Score

                10
                Unlock Smart Score
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                -21.86%
                12-Months-Change

                Fundamentals

                Return on Equity
                -150.23%
                Trailing 12-Months
                Asset Growth
                -0.32%
                Trailing 12-Months

                Company Description

                Cyclerion Therapeutics,Inc.

                Cyclerion Therapeutics, Inc. engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Aldeyra Therapeutics
                Edesa Biotech
                Genprex
                Forte Biosciences
                Popular Stocks
                ---
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis